Bullish
Pfizer Inc. has been cleared of allegations that it colluded with other pharmaceutical companies to fix the price of generic drugs. A US District Cour...
Bullish
Pfizer Inc. (PFE) is conducting a Phase 3 clinical trial for a new multivalent pneumococcal conjugate vaccine, PG4, aimed at providing "catch-up" vacc...
Neutral
Nike has appointed David Denton, former CFO of Pfizer and Lowe's, as its new executive vice president and chief financial officer, effective August 17...
Neutral
Nike Inc. has announced the hiring of David Denton, currently CFO at Pfizer Inc., to become its new chief financial officer. Denton will assume the ro...
Bullish
A federal appeals court has upheld a lower court's decision in favor of Pfizer in a patent dispute with Enanta Pharmaceuticals over Pfizer's COVID-19 ...
Neutral
Pfizer's experimental cancer drug, sigvotatug vedotin, acquired in the Seagen deal, failed a Phase 3 lung cancer study by not significantly extending ...
Neutral
The Federal Circuit Court of Appeals upheld the cancellation of Enanta Pharmaceuticals Inc.'s patent, rejecting their infringement claim against Pfize...
Neutral
Pfizer Inc. (NYSE: PFE) is inviting the public to a webcast of a conference call with investment analysts on Tuesday, August 4, 2026, at 10:00 a.m. ED...
Neutral
Pfizer Inc. (NYSE: PFE) has announced that its Chief Financial Officer, Dave Denton, will step down on August 15 to pursue a new opportunity in the co...
Neutral
Pfizer recently announced a CFO transition, with Dave Denton leaving and Cecile Guegan stepping in as interim CFO, alongside FDA approval for HYMPAVZI...
Neutral
E. Ohman J or Asset Management AB lifted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 41.6% in the first quarter, according to its most recent...
Neutral
Kovitz Investment Group Partners LLC cut its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 52.2% during the fourth quarter, according to the com...
Bearish
Pfizer's stock fell after the company announced that CFO Dave Denton will step down on August 15 to take a position outside the healthcare sector. Cec...
This article examines three healthcare stocks—Pfizer (PFE), Tempus AI (TEM), and Medtronic (MDT)—that are leveraging artificial intelligence. It highl...
Neutral
Macquarie Group Ltd. lowered its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 24.7% during the 4th quarter, Holdings Channel reports. The institut...
Neutral
Pfizer (NYSE:PFE) has been highlighted as one of the best longevity stocks to buy, based on recent FDA approvals and promising clinical trial results....
Neutral
Pfizer stock gained 2.8% after RBC Capital Markets upgraded its rating from "underperform" to "sector perform," removing its prior sell rating. The up...
Neutral
Pfizer CEO Albert Bourla presented at the Goldman Sachs 47th Annual Global Healthcare Conference, addressing concerns about revenue loss post-COVID de...
Pfizer CEO Albert Bourla has warned that the company is reviewing its planned investments in Germany due to proposed government policies aimed at lowe...
Neutral
Pfizer is facing a post-COVID slump due to expiring patents on blockbuster drugs and decreased demand for its COVID-19 products. To counter this, the ...